FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549	
------------------------	--

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Wellisch Alejandro D				2. Issuer Name <b>and</b> Ticker or Trading Symbol ABBOTT LABORATORIES [ ABT ]							(Ched	ck all applic Directo	ionship of Reporting all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	vner			
(Last)	(Fi BOTT PARI	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/19/2021						X	below)			below)	·			
(Street) ABBOT	ΓPARK IL		60064 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Ind Line) X							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transa Date (Month/D	Execution Date,			Code (Instr. 5)				4 and Securitie Benefici Owned F Reporte		es Forn ally (D) o following (I) (II		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	V	Amount	nt (A) or (D)		ice	Transact (Instr. 3 a							
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
			ransaction of ode (Instr. Derivative			Expiration Date of Si (Month/Day/Year) Und Deri			7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivativ Security Curity (Instr. 5)				Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Co	ode	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amo or Num of Shar	ber					
Option (right to buy) <sup>(1)</sup>	\$124.04	02/19/2021			A		39,994		02/19/2022	2 0	2/18/2031	Common Shares	39,9	994	\$0	39,994	4	D	

## **Explanation of Responses:**

1. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,331 on February 19, 2022, 13,331 on February 19, 2023, and 13,332 on February 19, 2024.

/s/ Alejandro D. Wellisch by

Jessica H. Paik, Attorney-in-

\*\* Signature of Reporting Person Date

02/23/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.